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Pulmonary Cyclooxygenase-1 (COX-1) and COX-2 Cellular Expression
and Distribution After Respiratory Syncytial Virus and Parainfluenza Virus
Infection
Abstract
Prostaglandins (PGs) play an important role in pulmonary physiology and various pathophysiological
processes following infection. The initial step in the biosynthesis of PGs is regulated by two distinct
cyclooxygenase enzymes, cyclooxygenase-1 (COX-1) and COX-2. The goal of this study was to investigate the
pulmonary cellular localization and distribution of COX-1 and COX-2 in a neonatal lamb model following
respiratory syncytial virus (RSV) and parainfluenza virus 3 (PI3) infection, organisms that also cause
significant respiratory disease in children. No significant differences were seen in pulmonary COX-1
expression at various microanatomical locations following RSV or PI3 infection compared to controls. In
contrast, COX-2 was upregulated following RSV and PI3 infection. Strong expression was restricted to
bronchial and bronchiolar epithelial cells and macrophages, while minimal expression was present in the same
microanatomical locations in the uninfected lungs. Other microanatomical locations in both the controls and
the infected lungs lacked expression. This work suggests that during RSV or PI3 infection: (1) COX-1 cellular
expression is not altered, (2) COX-2 cellular expression is upregulated in airway bronchiolar and bronchial
epithelial cells and macrophages, (3) respiratory epithelium along with macrophages are important
microanatomical compartments regulating the host inflammatory response during viral infection, and (4)
COX-2 may be a potential target for RSV and PI3 therapy.
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Abstract
Prostaglandins (PGs) play an important role in pulmonary physiology and various pathophysiological processes
following infection. The initial step in the biosynthesis of PGs is regulated by two distinct cyclooxygenase
enzymes, cyclooxygenase-1 (COX-1) and COX-2. The goal of this study was to investigate the pulmonary
cellular localization and distribution of COX-1 and COX-2 in a neonatal lamb model following respiratory
syncytial virus (RSV) and parainfluenza virus 3 (PI3) infection, organisms that also cause significant respiratory
disease in children. No significant differences were seen in pulmonary COX-1 expression at various micro-
anatomical locations following RSV or PI3 infection compared to controls. In contrast, COX-2 was upregulated
following RSV and PI3 infection. Strong expression was restricted to bronchial and bronchiolar epithelial cells
and macrophages, while minimal expression was present in the same microanatomical locations in the unin-
fected lungs. Other microanatomical locations in both the controls and the infected lungs lacked expression. This
work suggests that during RSV or PI3 infection: (1) COX-1 cellular expression is not altered, (2) COX-2 cellular
expression is upregulated in airway bronchiolar and bronchial epithelial cells and macrophages, (3) respiratory
epithelium along with macrophages are important microanatomical compartments regulating the host inflam-
matory response during viral infection, and (4) COX-2 may be a potential target for RSV and PI3 therapy.
Introduction
Prostaglandins (PGs) are synthesized from arachi-donic acid by enzymatic reactions. Cyclooxygenase-
derived PGs have two distinct isoenzymes, COX-1 and COX-2.
COX-1 is constitutively expressed, is found in most normal
body tissues, and is involved in physiological processes. COX-2
is expressed in normal tissues at very low levels, but is highly
induced by proinflammatory mediators in the setting of in-
flammation, injury, and pain (30).
In the lung, COX pathways are among the many different
mediators involved in various physiological and patho-
physiological processes, such as regulation of vascular tone
(20), pulmonary fibrosis and tissue remodeling (45), surfac-
tant homeostasis (2), alveolar macrophages and their role in
pulmonary defense (31,46), bronchial mucus secretion (38),
and the pathogenesis of asthma and chronic obstructive
pulmonary disease (COPD) (29,33). Additionally, marked
increases in prostaglandin E2 (PGE2) synthesis and upregu-
lation of COX-2 have been reported in acid-induced epithe-
lial injury (6), suggesting that COX plays an integral role in
the pulmonary system.
Both respiratory syncytial virus (RSV) and parainfluenza
viruses (PIs) are pathogens of human infants and perinatal
lambs. RSV and PI are leading viral causes of respiratory
disease in infants in their first year of life, and cause mor-
bidity and mortality in transplant patients and older adults
(15,41). Bovine and ovine strains of both RSV and para-
myxoviruses have high homology to human strains and
induce identical pulmonary lesions (9,16,17,23,25,27). Sev-
eral proinflammatory cytokines and chemokines can be
detected in patients with RSV and PI infection (5,7,15,21).
Increased levels of PGE2 in the plasma or endotracheal as-
pirates have been demonstrated in animals and infants in-
fected with RSV (14,37). In addition, RSV-induces PGE2
production in human alveolar type II-like epithelial cells
(26). However, to the best of our knowledge, COX cellular
expression and distribution following RSV or PI3 infection
in human or animal models of RSV or PI3 pulmonary in-
fection has not been evaluated.
1Drug Safety Research and Development, Pfizer Global Research and Development, St. Louis Laboratories, St. Louis, Missouri.
2Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, Iowa.
3Department of Veterinary Pathology, Iowa State University College of Veterinary Medicine, Ames, Iowa.
VIRAL IMMUNOLOGY
Volume 23, Number 1, 2010
ª Mary Ann Liebert, Inc.
Pp. 43–48
DOI: 10.1089=vim.2009.0042
43
Therefore, we investigated the pulmonary microanatomi-
cal location and cellular expression of COX-1 and COX-2 in
lung tissues obtained from a lamb pulmonary model infected
with RSV or PI3. This study is the first reported analysis of
the pulmonary microanatomical expression of COX-1 and
COX-2 in a neonatal lamb model of paramyxoviral infection.
Materials and Methods
Experimental animal model, respiratory viruses,
and animal inoculations
A total of 20 neonatal lambs (3–5 d of age) were used in
the study. These included: (1) control (saline) inoculated
(n¼ 8), (2) respiratory syncytial virus–infected (bovine strain)
lambs (n¼ 8), and (3) parainfluenza virus-3–infected (ovine
strain) lambs (n¼ 4). The PI3 viral inoculum consisted of
infectious supernatant prepared from a culture of ovine fetal
turbinate cells previously infected with ovine PI3 virus strain
DH-1, and the lambs received 10mL of 106.9 tissue culture
infective doses50 (TCID50) per milliliter intratracheally, and
the lambs were inoculated with 10mL of PI3. The RSV strain
375 was grown on bovine turbinate cells to a concentration of
107 TCID50 per milliliter, and the lambs received 10mL of
RSV (16,27). The control group was given saline.
Pulmonary tissues
On day 6 of infection, the time of peak lesion severity for
both RSV and PI3 (16,27), the lambs were euthanized with an
intravenous injection of sodium pentobarbital. The thorax
was opened and the lungs were then removed from for tissue
collection. The lungs were consistently sampled from the left
and right cranial, middle, and caudal lobes. The tissues were
fixed in 10% neutral buffered formalin for 24h and embedded
in paraffin wax. Sections were cut (3mm) and stained im-
munohistochemically with antibodies to COX-1 and COX-2.
COX-1 and COX-2 expression
by immunohistochemistry
Immunohistochemical (IHC) staining was conducted as
previously described (31). Sections (3-mm thick) were mounted
on positively-charged glass slides, dried, and then loaded on
the automated immunostainer at 378C, and we used a Ven-
tana Discovery XT device (Ventana Medical Systems, Tucson,
AZ) to analyze COX-1 and COX-2 expression. The slides were
deparaffinized and rehydrated. The sections were incubated
for 30min with serum-free DakoCytomation protein blocker
(Dako Corporation, Dako, CA), and then rinsed and incu-
bated for 4min with avidin-biotin blocking solution (Ventana
Medical Systems). Heat-induced epitope antigen retrieval was
completed using a Ventana specialty solution (pH¼ 8) (Ven-
tana Medical Systems).
Automation included exposure to 100 mL of primary anti-
COX-1 (1:200) or anti-COX-2 (1:50), rabbit polyclonal anti-
body (Cayman Chemical, Ann Arbor, MI) diluted using
reagent diluent (Ventana Medical Systems) at 378C for
60min. Then 100 mL of the appropriate anti-rabbit biotiny-
lated IgG (HþL) linking solution (Vector Laboratories,
Burlingame, CA) was applied to each section at 1:1000 di-
lution for 30min at room temperature. The sections were
again rinsed and allowed to react with 100mL of diamino-
benzidine (DAB detection kit) substrate solution (Ventana
Medical Systems) for 8min, followed by counterstaining
with hematoxylin then bluing reagent for 4min each,
removed from the autostainer, washed in warm water, de-
hydrated using graded alcohol, cleared in xylene, and cover-
slipped. Control reactions included: (1) sections incubated
with the omission of primary antibody and processed as
mentioned above, and (2) sections incubated with normal
rabbit serum instead of the primary antibody and processed
as above. The IHC distribution and intensity scoring system
consisted of: (–)¼no expression, (þ)¼ earliest weak minimal
detectable expression; (þþ)¼mild expression in up to 30%
of pulmonary cell types; (þþþ)¼moderate expression in
30–60% of pulmonary cell types; and (þþþþ)¼ strong ex-
pression with >60% of pulmonary cell types.
Results
Clinical signs, gross pathology, and histopathology lesions
from these animals were published previously (16). Briefly,
both PI3- and RSV-infected animals had increased tempera-
tures compared to controls. Gross pathology lesions were
characterized by multifocal areas of red to light-red areas of
consolidated regions (often 1–3mm in size). Microscopically,
the lambs had bronchiolitis characterized by slightly dilated
bronchiolar lumens partially filled with neutrophils, cell
debris, and occasional sloughed epithelial cells, with mild
multifocal erosions. Occasional syncytial cells were present
in multifocal bronchiolar lumens. Bronchiolar adventitia and
alveolar septa contained mild infiltrates of lymphocytes,
plasma cells, and occasional macrophages. Alveolar lumens
were often partially collapsed and partially filled with sero-
proteinaceous fluid, alveolar macrophages, and cell debris.
The pulmonary cellular expression and distribution of
COX-1 and COX-2 during RSV and PI3 infection are sum-
marized in Tables 1 and 2. Staining intensity ranged from
none (–) to strong (þþþþ). Strong (þþþþ) COX-1 expres-
sion was present in macrophages, bronchial and bronchiolar
smooth muscle cells, vascular endothelial cells, and vascular
smooth muscle cells, in lungs from control, RSV-infected,
and PI3-infected neonatal lambs (Fig. 1A, B, and C). Intense
expression also occurred at sites of inflammation and injury,
and correlated with the degree of inflammation and infec-
tion. Moderate (þþþ) COX-1 staining was present in alve-
olar septa in control and PI3-infected lungs. Alveolar septa
from RSV-infected lungs had strong (þþþþ) COX-1 ex-
Table 1. Pulmonary Cellular Expression
of COX-1 After RSV and PI3 Infection
Pulmonary compartment Control RSV PI3
Alveolar septae þþþ þþþþ þþþ
Bronchial epithelium þ þþ þ
Bronchial SMC þþþþ þþþþ þþþþ
Bronchiolar epithelium þ þþ þ
Bronchiolar SMC þþþþ þþþþ þþþþ
Macrophages þþþþ þþþþ þþþþ
Vascular EC þþþþ þþþþ þþþþ
Vascular SMC þþþþ þþþþ þþþþ
()¼No staining; (þ)¼minimal expression; (þþ)¼mild expres-
sion; (þþþ)¼moderate expression; (þþþþ)¼ strong expression.
Abbreviations: EC, endothelial cells; SMC, smooth muscle cells.
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pression. Mild (þþ) COX-1 expression was present in
bronchial and bronchiolar epithelial cells from RSV-infected
lungs, while minimal (þ) expression was present in lungs
from either control or PI3-infected lungs. Bronchiolar epi-
thelium in sections from control and PI3-infected lungs had
minimal staining, while mild staining was present in sections
from RSV-infected lungs.
COX-2 expression was minimally present in macrophages
from control lungs, while strong (þþþþ) expression was
present in macrophages in RSV- and PI3-infected lungs (Fig.
2A, B, and C). Strong (þþþþ) COX-2 expression was pres-
ent in bronchial epithelium from both PI3-infected and RSV-
infected lungs. Bronchial epithelium from control lungs had
minimal COX-2 expression. Similarly, strong (þþþþ) COX-2
expression was present in the bronchiolar epithelium of both
RSV-infected and PI3-infected lungs, with control lungs had
minimal (þ) COX-2 expression. Alveolar septa, bronchial
and bronchiolar smooth muscle cells, and vascular endo-
thelial and smooth muscle cells lacked COX-2 expression in
control and infected lungs (–). Intense expression was pres-
ent at sites of infection and inflammation and correlated with
the degree of inflammation and infection.
Discussion
Pulmonary epithelial cells play an integral role in airway
homeostasis, perform numerous biological functions, and
represent the first line of defense against infection (39).
Prostanoids, generated by COX, are present in high con-
centrations during various pulmonary disease conditions,
such as acute respiratory distress syndrome (ARDS), asthma,
COPD, and sepsis (13,29,42). In addition, increased COX-2
expression has been demonstrated in various viral infections
(36). Prostanoids are important mediators in both normal
and pathological pulmonary functions. All microanatomical
Table 2. Pulmonary Cellular Expression
of COX-2 After RSV and PI3 Infection
Pulmonary compartment Control RSV PI3
Alveolar septae   
Bronchial epithelium þ þþþþ þþþþ
Bronchial SMC   
Bronchiolar epithelium þ þþþþ þþþþ
Bronchiolar SMC   
Macrophages þ þþþþ þþþþ
Vascular EC   
Vascular SMC   
()¼No staining; (þ)¼minimal expression; (þþ)¼mild expres-
sion; (þþþ)¼moderate expression; (þþþþ)¼ strong expression.
Abbreviations: EC, endothelial cells; SMC, smooth muscle cells.
FIG. 1. (A) COX-1 expression in the lung from a control
lamb. Strong (þþþþ) expression in bronchial smooth mus-
cle cells (long arrows) and macrophages (arrowheads) can be
seen (immunohistochemical stain, original magnification
10). (B) COX-1 expression in the lung from a RSV-infected
lamb. Strong (þþþþ) expression in bronchial smooth
muscle cells (long arrows), alveolar septa (short arrows), and
vascular endothelial cells (arrowheads) can be seen
(immunohistochemical stain, original magnification 10).
(C) COX-1 expression in the lung from a PI3-infected lamb.
Strong (þþþþ) expression in bronchial and bronchiolar
smooth muscle cells (long arrows) and vascular endothelial
cells (arrowheads) can be seen (immunohistochemical stain,
original magnification 10).
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locations in control, RSV-infected, and PI3-infected lungs had
some degree of COX-1 expression in our study. This finding
is consistent with other studies demonstrating COX-1 ex-
pression in various pulmonary microanatomical locations in
normal human lungs (18). COX-1-dependent prostanoid gen-
eration has also been associated with regulation of bronchial
tone (11). In lungs from normal animal models, COX-1 was
present in bronchiolar epithelium and smooth muscle, alve-
olar macrophages, endothelial cells, and vascular smooth
muscle cells of the rat (11), and in vascular endothelium and
alveolar epithelial cells in the non-human primate (24). In
lungs of sheep, COX-1 was present in endothelial cells and
airway epithelium, and have critical involvement in vaso-
dilatation, bronchodilation, and surfactant synthesis (8). The
strong COX-1 expression in macrophages seen in our study
is in accordance with results of other studies in rats, indi-
cating that COX-1 was largely responsible for the enzyme
activity displayed by alveolar macrophages (46).
Bronchial epithelial cells are known to play an integral role
in airway defenses via mucociliary clearance, and they also
constitute a mechanical barrier. In addition, bronchial epi-
thelial cells produce and release biologically active com-
pounds, including lipid mediators, growth factors, and a
variety of cytokines important in the pathogenesis of airway
disorders (40). Some in-vitro studies have demonstrated that
cultured human bronchial epithelial cells express COX-2
constitutively (3). In addition, COX-2 expression was found
in bronchial epithelium obtained from normal human sub-
jects (10). RSV is a leading cause of respiratory infection and
hospitalization in young children, especially those born
preterm (17). Likewise, PI1 and PI3 are important causes of
seasonal respiratory disease in human infants (17). Sheep are
also susceptible to ovine and bovine strains of RSV and ovine
strains of PI3. All of these strains have a very high degree of
homology and induce similar lung lesions in both perinatal
lambs and humans (9,16,17,23,27). The role of prostanoids in
modulating RSV or PI3 infection in vivo is unknown. A
slightly higher level of COX-1 expression was present in
bronchial and bronchiolar epithelial cells from RSV-infected
lungs compared to controls and PI3-infected lungs. The
marked increase in COX-2 expression in pulmonary bron-
chial and bronchiolar epithelium and macrophages following
RSV or PI3 infection found in our study is consistent with the
known role of respiratory epithelia as the first line of defense
during infection.
The airway epithelium forms a continuous barrier that
limits the access of luminal substances to the systemic cir-
culation (43). In a human airway epithelial cell culture sys-
tem, COX-2 induction has been observed in the setting of
inflammatory cytokine stimulation (44). Significant induction
FIG. 2. (A) COX-2 expression in the lung from a control
lamb. Minimal (þ) expression in bronchial and bronchiolar
epithelial cells (long arrows) can be seen (immunohisto-
chemical stain, original magnification 10). (B) COX-2
expression in the lung from an RSV-infected lamb. Strong
(þþþþ) expression in bronchiolar epithelial cells (long
arrows) and macrophages (short arrows) can be seen
(immunohistochemical stain, original magnification 10).
(C) COX-2 expression in the lung from a PI3-infected lamb.
Strong (þþþþ) expression in bronchial epithelial cells (long
arrows) and macrophages (short arrows) can be seen
(immunohistochemical stain, original magnification 10).
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of COX-2 expression and activity was also observed in an
experimental mouse model of acute lung injury (12). Mini-
mal COX-2 expression was present in bronchial and bron-
chiolar epithelial cells from control animals, but was
increased in RSV- and PI3-infected animals in our study. This
observation corroborates results of other studies that have
demonstrated low levels of COX-2 in untreated human air-
way epithelial cells in culture (28). It has been shown in
in-vitro human alveolar type II-like epithelial cells that RSV
infection induces a time-dependent increase in COX-2 ex-
pression, is a potent inducer of PGE2, and that viral repli-
cation is required for PGE2 secretion (26). In addition, strong
induction of COX-2 expression during RSV infection in vitro,
in human lung alveolar epithelial cells, and in vivo in lungs of
cotton rats infected with RSV has been demonstrated (32).
However, the exact pulmonary cellular source of the in-
creased COX-2 was not determined in the study by Ri-
chardson et al. (32). The lack of COX-2 expression in
pulmonary vascular endothelial cells found in our study is
consistent with other in-vitro studies in which no COX-2 was
detected in these cells under basal conditions (22).
The marked increase in COX-2 expression in macrophages
is consistent with the finding that alveolar macrophages are a
major source of PGE2 (19). Macrophages are postulated to be
the primary cell type expressing COX-2 and producing PGs
at sites of inflammation (34). In a mouse model of oxygen-
induced ARDS, COX-2 was expressed in alveolar macro-
phages (1). Increased COX-2 levels in macrophages have
been demonstrated in humans after rhinovirus infection (35).
COX-2 was induced in RSV-infected cotton rat alveolar and
peritoneal macrophages (32). In addition, human cord blood-
derived macrophages and dendritic cells have been shown to
secrete PGE2 following exposure to RSV (4).
Conclusion
Collectively, the findings in this work suggest that in an
in-vivo neonatal lamb model: (1) COX-1 expression is not
altered after RSV or PI3 pulmonary infection, (2) COX-2 ex-
pression is upregulated in bronchiolar and bronchial epi-
thelial cells and macrophages after RSV and PI3 infection, (3)
respiratory epithelia along with macrophages are important
microanatomical compartments regulating the host inflam-
matory response during viral infection, and (4) COX-2 may
be a potential target for RSV and PI3 therapy.
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